{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:32:27Z","timestamp":1794317547413,"version":"4.9.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the performance of a commercial line immunoassay (LIA) in cohorts of healthy controls (HC), disease controls (DC) and patients with idiopathic inflammatory myopathies (IIMs) and investigate whether different cut-offs would enhance the accuracy of myositis antibodies (MAs) by LIA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Sera from patients with positive MAs (n\u2009=\u2009118), DC (n\u2009=\u2009124) and HC (n\u2009=\u200960), were analysed for MAs using EUROLINE Myopathies 16 Ag LIA (EUROIMMUN).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The newly established MAs cut-offs resulted in significantly lower both false-positive and multiple positive rates compared with the manufacturer\u2019s single cut-off, from 36.7% to 5.0% and 7.2% to 1.1% in controls, and 45.8% to 23.8% and 23.7% to 15.5% in patients with positive MAs cohorts, respectively. Furthermore, the positive predictive value (PPV) of MAs for IIMs or interstitial lung disease (ILD) increased significantly from 47.5% to 66.7%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Establishment of local cut-offs and cross-reference ANA findings can significantly enhance the assay\u2019s performance and increase the confidence in interpreting MAs results by LIA. It is important to be aware of the low PPV for most MAs in real-world cohorts; thus, the investigation of MAs should be approached as confirmatory or differential diagnosis rather than a screening tool in IIMs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf101","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T16:25:01Z","timestamp":1739550301000},"page":"4364-4370","source":"Crossref","is-referenced-by-count":5,"title":["Cut-off matters in the interpretation of myositis antibodies by line immunoassay"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2748-1222","authenticated-orcid":false,"given":"Xiumei","family":"Wei","sequence":"first","affiliation":[{"name":"South Eastern Sydney Immunology Laboratory, NSW Health Pathology , Sydney, NSW,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3482-5663","authenticated-orcid":false,"given":"James","family":"Yun","sequence":"additional","affiliation":[{"name":"South Eastern Sydney Immunology Laboratory, NSW Health Pathology , Sydney, NSW,","place":["Australia"]},{"name":"Clinical Immunology, Prince of Wales Hospital , Sydney, NSW,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of New South Wales , Sydney, NSW,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5363-7062","authenticated-orcid":false,"given":"Jianna","family":"He","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, St George Hospital , Sydney, NSW,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Sturgess","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, University of New South Wales , Sydney, NSW,","place":["Australia"]},{"name":"Department of Rheumatology, St George Hospital , Sydney, NSW,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"2025070205020310300_keaf101-B1","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025070205020310300_keaf101-B2","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/art.30344","article-title":"Correlation of anti\u2013signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy","volume":"63","author":"Benveniste","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025070205020310300_keaf101-B3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025070205020310300_keaf101-B4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5\u2019-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"key":"2025070205020310300_keaf101-B5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"key":"2025070205020310300_keaf101-B6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2025070205020310300_keaf101-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","article-title":"Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera","volume":"433","author":"Cavazzana","year":"2016","journal-title":"J Immunol Methods"},{"key":"2025070205020310300_keaf101-B8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/annrheumdis-2018-214690","article-title":"Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies","volume":"78","author":"Espinosa-Ortega","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025070205020310300_keaf101-B9","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3389\/fimmu.2019.00848","article-title":"Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies","volume":"10","author":"Mahler","year":"2019","journal-title":"Front Immunol"},{"key":"2025070205020310300_keaf101-B10","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025070205020310300_keaf101-B11","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/rheumatology\/keae167","article-title":"Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort","volume":"63","author":"Loganathan","year":"2024","journal-title":"Rheumatology"},{"key":"2025070205020310300_keaf101-B12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12026-017-8974-3","article-title":"Reflex testing of speckled cytoplasmic patterns observed in routine ANA HEp-2 indirect immunofluorescence with a multiplex anti-synthetase dot-blot assay: a multicentric pilot study","volume":"66","author":"Infantino","year":"2018","journal-title":"Immunol Res"},{"key":"2025070205020310300_keaf101-B13","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/rheumatology\/key451","article-title":"Combining immunofluorescence with immunoblot assay improves the specificity of autoantibody testing for myositis","volume":"58","author":"Infantino","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025070205020310300_keaf101-B14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s12026-015-8774-6","article-title":"Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study","volume":"64","author":"Picard","year":"2016","journal-title":"Immunol Res"},{"key":"2025070205020310300_keaf101-B15","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.autrev.2016.09.005","article-title":"Statin-associated autoimmune myopathy: a distinct new IFL pattern can increase the rate of HMGCR antibody detection by clinical laboratories","volume":"15","author":"Alvarado-Cardenas","year":"2016","journal-title":"Autoimmunity reviews"},{"key":"2025070205020310300_keaf101-B16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/1744666X.2019.1699059","article-title":"Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis","volume":"16","author":"Gono","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"2025070205020310300_keaf101-B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025070205020310300_keaf101-B18","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1093\/rheumatology\/keac039","article-title":"Concordance between myositis autoantibodies and anti-nuclear antibody patterns in a real-world, Australian cohort","volume":"61","author":"He","year":"2022","journal-title":"Rheumatology"},{"key":"2025070205020310300_keaf101-B19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pathol.2016.03.012","article-title":"Diagnostic performance of a commercial immunoblot assay for myositis antibody testing","volume":"48","author":"Bundell","year":"2016","journal-title":"Pathology"},{"key":"2025070205020310300_keaf101-B20","doi-asserted-by":"crossref","first-page":"e7-e7","DOI":"10.1136\/annrheumdis-2017-212915","article-title":"Detection of myositis-specific antibodies","volume":"78","author":"Vulsteke","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025070205020310300_keaf101-B21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s41927-020-00132-9","article-title":"Line blot immunoassays in idiopathic inflammatory myopathies: retrospective review of diagnostic accuracy and factors predicting true positive results","volume":"4","author":"To","year":"2020","journal-title":"BMC Rheumatol"},{"key":"2025070205020310300_keaf101-B22","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2025070205020310300_keaf101-B23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"2025070205020310300_keaf101-B24","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.3390\/diagnostics11122246","article-title":"Profiling of myositis specific antibodies and composite scores as an aid in the differential diagnosis of autoimmune myopathies","volume":"11","author":"Mahler","year":"2021","journal-title":"Diagnostics"},{"key":"2025070205020310300_keaf101-B25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.autrev.2009.03.005","article-title":"Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies","volume":"9","author":"R\u00f6nnelid","year":"2009","journal-title":"Autoimmun Rev"},{"key":"2025070205020310300_keaf101-B26","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","article-title":"Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay","volume":"49","author":"Ghirardello","year":"2010","journal-title":"Rheumatology"},{"key":"2025070205020310300_keaf101-B27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3899\/jrheum.160618","article-title":"A negative antinuclear antibody does not indicate autoantibody negativity in myositis: role of anticytoplasmic antibody as a screening test for antisynthetase syndrome","volume":"44","author":"Aggarwal","year":"2017","journal-title":"J Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf101\/61899601\/keaf101.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/7\/4364\/61899601\/keaf101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/7\/4364\/61899601\/keaf101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:02:14Z","timestamp":1751446934000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/7\/4364\/8015629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,2,14]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf101","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,2,14]]}}}